Immunocore Holdings plc (FRA:6YG)
Germany · Delayed Price · Currency is EUR | Market Cap | 1.42B +1.0% |
| Revenue (ttm) | 377.06M +21.0% |
| Net Income | -15.82M |
| EPS | -0.32 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 150 |
| Open | 28.00 |
| Previous Close | 28.40 |
| Day's Range | 27.00 - 28.00 |
| 52-Week Range | 23.20 - 35.60 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 6, 2026 |
About Immunocore Holdings
Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebentafusp which is in Phase 3 clinical trial for the treatment of advanced cutaneous melanoma and adjuvant uveal melanoma; brenetafusp which is in Phase ... [Read more]
Financial Performance
In 2025, Immunocore Holdings's revenue was $400.02 million, an increase of 28.95% compared to the previous year's $310.20 million. Losses were -$35.51 million, -30.48% less than in 2024.
Financial numbers in USD Financial StatementsNews
Immunocore doses first patient in IMC-S118AI trial
Immunocore (IMCR) announced that the first patient with type 1 diabetes, or T1D, has been dosed in the Phase 1 trial of IMC-S118AI. The Phase 1 dose escalation trial will…
Immunocore announces first patient dosed in the Phase 1 trial of IMC-S118AI – its first tissue-specific autoimmune candidate – for patients with type 1 diabetes
Immunocore announces first patient dosed in the Phase 1 trial of IMC-S118AI – its first tissue-specific autoimmune candidate – for patients with type 1 diabetes The Phase 1 trial will assess the safet...
Immunocore Holdings Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
China-origin innovation is intensifying competition, shifting focus to complex, hard-to-copy targets. AI is streamlining R&D, while KIMMTRAK maintains strong market penetration and is poised for expansion pending positive trial results. The pipeline spans oncology, autoimmune, and infectious diseases, with disciplined capital allocation and potential partnerships supporting future growth.
Immunocore achieves target patient enrollment in TEBE-AM clinical trial
Immunocore (IMCR) announced the achievement of target patient enrollment in the TEBE-AM clinical trial. With target enrollment now achieved, patients enrolled in the trial will continue to be followed...
Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanoma
Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK ® (tebentafusp) in previously treated advanced melanoma Topline overall survival data expected as ea...
Immunocore Holdings Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
A commercial-stage biotech highlighted strong KIMMTRAK sales, robust cash reserves, and a pipeline with three phase III trials nearing key data readouts. Expansion into new indications and ongoing innovation in TCR therapies position the company for multiple value-creating milestones in the next two to three years.
Immunocore to present at upcoming investor conferences
Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & RADNOR, PA & GAITHERSBURG, MD, US, 1 September 2026) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company...
Immunocore reinstated with an Overweight at JPMorgan
JPMorgan analyst Jessica Fye reinstated coverage of Immunocore (IMCR) with an Overweight rating and $50 price target The firm thinks Kimmtrak offers a “solid foundation” that is still growing in…
Immunocore price target raised to $43 from $40 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Immunocore (IMCR) to $43 from $40 and keeps an Equal Weight rating on the shares.
Immunocore Holdings Earnings Call Transcript: Q2 2026
Strong H1 2026 revenue growth was driven by KIMMTRAK's commercial momentum and high market penetration, with five-year survival data reinforcing its clinical value. Pipeline progress continues across melanoma, ovarian, lung, HIV, and autoimmune diseases, supported by a robust balance sheet.
Immunocore Holdings Earnings release: Q2 2026
Immunocore Holdings released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Immunocore Holdings Quarterly report: Q2 2026
Immunocore Holdings has published its Q2 2026 quarterly earnings report on August 6, 2026.
Immunocore Holdings Slides: Q2 2026
Immunocore Holdings has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 6, 2026.
Immunocore reports second quarter financial results and provides a business update
Immunocore reports second quarter financial results and provides a business update KIMMTRAK ® (tebentafusp-tebn) net revenues of $115.9 million in Q2 2026, growing by 18% year-over-year Enrollment in ...
Immunocore Holdings Slides: Corporate presentation
Immunocore Holdings has posted slides in relation to its latest quarterly earnings report, which was published on August 5, 2026.
Immunocore price target raised to $35 from $34 at Mizuho
Mizuho analyst Graig Suvannavejh raised the firm’s price target on Immunocore (IMCR) to $35 from $34 and keeps a Neutral rating on the shares. The firm updated models in the…
Immunocore price target raised to $35 from $34 at Mizuho
Mizuho raised the firm’s price target on Immunocore (IMCR) to $35 from $34 and keeps an Underperform rating on the shares.
Immunocore to report second quarter 2026 financial results and host call on August 6, 2026
Immunocore to report second quarter 2026 financial results and host call on August 6, 2026 (OXFORDSHIRE, England & RADNOR, PA & GAITHERSBURG, MD, US, 30 July 2026) Immunocore Holdings plc (Nasdaq: IMC...
Immunocore presents updated results from Phase 1/2 trial of brenetafusp
Immunocore (IMCR) announced updated results from its Phase 1/2 trial evaluating brenetafusp in patients with heavily pretreated advanced melanoma. The data is presented in a poster at the 2026 America...
Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma
Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma Brenetafusp monotherapy resulted in a 6-month overall survival rate of 87% and disease con...
Immunocore Holdings Slides: Corporate presentation
Immunocore Holdings has posted slides in relation to its latest quarterly earnings report, which was published on May 13, 2026.
Immunocore reports first quarter financial results and provides a business update
Immunocore reports first quarter financial results and provides a business update KIMMTRAK ® (tebentafusp-tebn) Q1 net sales of $106.7 million, growing by 14% year-over-year Oral presentation at AACR:...
Immunocore Holdings Quarterly report: Q1 2026
Immunocore Holdings has published its Q1 2026 quarterly earnings report on May 6, 2026.
Immunocore Holdings Earnings release: Q1 2026
Immunocore Holdings released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
Immunocore announces five-year overall survival data for Kimmtrak
Immunocore (IMCR) announced that Kimmtrak five-year overall survival, OS, was presented in an oral session at the American Association for Cancer Research, AACR, 2026 meeting. This is the longest, pro...